HOME >> MEDICINE >> NEWS
REVLIMID(R) granted approval by FDA for treatment of multiple myeloma

Summit, N.J., June 29 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional indication for REVLIMID (lenalidomide), for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. REVLIMID is also approved for use in the treatment of patients with transfusion-dependent anemia due to Low-or- Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Multiple myeloma is the second most common blood cancer in the United States, affecting approximately 50,000 people. About 14,600 new cases of multiple myeloma are diagnosed each year and about 12,000 Americans are expected to die of multiple myeloma in 2006. In the REVLIMID (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group. Most adverse events and Grade 3 or 4 adverse events were more frequent in patients who received the combination of REVLIMID (lenalidomide)/dexamethasone compared to placebo /dexamethasone.

"The FDA approval of REVLIMID offers a new oral therapeutic option to this particular group of patients with multiple myeloma," said Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance for Celgene. REVLIMID will be available in the following strengths: 5 mg, 10 mg, 15 mg, and 25 mg capsules.


'"/>

Contact: Brian P. Gill
bgill@celgene.com
908-673-9530
Weber Shandwick Worldwide
30-Jun-2006


Page: 1

Related medicine news :

1. Acrux granted first grant in Europe, triggering payment from Lilly
2. Four new us patents granted to Acrux for transdermal drug delivery
3. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
4. Sutent achieves first line EAU approval for kidney cancer
5. Breast cancer drug receives FDA approval
6. March of Dimes: Drug to prevent preterm birth needs prompt FDA approval
7. Worlds first approval of new HIV drug TMC114 provides potent new treatment option with FUZEON
8. Aussie of the Year wins approval for cervical cancer vaccine
9. UC Berkeley team helps win approval for life-saving drug for African women
10. Cincinnati Childrens applauds EU approval of rotavirus vaccine
11. TPV EU approval provides new HIV active drug to be combined with FUZEON

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2018)... ... August 07, 2018 , ... The American ... selected to receive the 2018 Board of Directors Student Scholarship . The ... of psychiatric-mental health nursing and develop the next generation of leaders in the ...
(Date:8/3/2018)... ... 2018 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... the Bible meant only to be understood in this current generation. Yisrayl says he ... decode passages that he says scholars have struggled with for generations. Yisrayl says the ...
(Date:8/2/2018)... Pa. (PRWEB) , ... August 02, 2018 , ... ... lifeIMAGE medical image e-sharing platform to connect clinicians inside and outside ... patients suffering a life-threatening stroke or trauma. , AHN joins other leading hospital ...
(Date:8/2/2018)... Conn. (PRWEB) , ... August 02, 2018 , ... ... (TGA) to its prestigious Top 20 Training Delivery Companies of 2018 . ... “Our mission is to empower training industry professionals with the game-based tools they ...
(Date:8/2/2018)... ... August 01, 2018 , ... Primary care practices in Rochester, ... makes actionable recommendations for victims and their doctors. , A team of researchers ... (RESOLVE) developed the software program. , “Family care practitioners are often the ...
Breaking Medicine News(10 mins):
(Date:8/15/2018)... ... 15, 2018 , ... During a special ceremony at the ... Illinois, was named the grand prize winner of the 2018 IsaBody Challenge®. The ... a global health and wellness company providing nutrition and lifestyle solutions. , ...
(Date:8/14/2018)... ... August 14, 2018 , ... ... commitment of more than $270,000 to expand a popular pet therapy program. ... full-time coordinator to facilitate more visits to patients throughout the hospital and outpatient ...
(Date:8/11/2018)... ... August 10, 2018 , ... Last month, Dr. Tim Herman, ... to deliver dental care in underserved communities surrounding its capital of Asunción. Along with ... Dr. Herman volunteered his time to help deliver care to over 550 individuals in ...
Breaking Medicine Technology:
Cached News: